Clinical Trial Update: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps [Phase 3]

View source ↗

Summary

Phase 3 results evaluate the efficacy and safety of Depemokimab (GSK3511294) in adults with chronic rhinosinusitis with nasal polyps. The study results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Depemokimab (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Nasal Polyps | Phase 3 | Status: COMPLETED | Results posted: 2025-12-03